GlassScriptPhysician profile
Jesse Andrew Coale
NPI 1629130216
$13,881.01
in general payments reported to CMS, 2019-2025
47 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,839 · 2022: $3,873 · 2023: $3,501 · 2024: $3,022 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,092 · Education: $77.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,091.51 |
| Education | $77.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,567.35 | 2021-2025 | |
| Novo Nordisk INC | $1,165.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,041.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,019.68 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $946.24 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $862.04 | 2021-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $718.68 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $558.15 | 2021-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $556.74 | 2021-2025 | Rexulti |
| Pfizer INC. | $501.48 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.81 | 2021-2024 | Xifaxan |
| Abbott Laboratories | $312.61 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $302.10 | 2021-2025 | Spravato |
| Amgen INC. | $290.92 | 2021-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $252.60 | 2021-2023 | Dificid, Steglatro, Belsomra |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Coale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.